Evidence map›Paper›PMID 42853491›Full record

ArticleInfection2026

Influenza vaccine effectiveness against hospitalization in children aged 6-72 months: a test-negative study in the Southern Italy, 2022-2026.

Francesca Fortunato, Angelo Campanozzi, Angelo Acquafredda, Matteo Mariano, Valeria Delli Carri, Tiziana Rollo, Loris Micelli, Dalila Tedeschi, Rosa Prato, Domenico Martinelli

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Francesca FortunatoHygiene Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. francesca.fortunato@unifg.it.
Angelo CampanozziPediatric Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Angelo AcquafreddaPediatric Unit, "G. Tatarella" Hospital, Foggia Local Health Unit, Foggia, Italy.
Matteo MarianoPediatric Unit, "T. Masselli Mascia" Hospital, Foggia Local Health Unit, Foggia, Italy.
Valeria Delli CarriMicrobiology and Virology Unit, Policlinico Foggia Hospital, Foggia, Italy.
Tiziana RolloMicrobiology and Virology Unit, Policlinico Foggia Hospital, Foggia, Italy.
Loris MicelliMicrobiology and Virology Unit, Policlinico Foggia Hospital, Foggia, Italy.
Dalila TedeschiPediatric Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Rosa PratoHygiene Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Domenico MartinelliHygiene Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeasonal influenza is an important cause of hospitalization in young children, yet real-world evidence on vaccine effectiveness (VE) against severe outcomes remains limited in Italy. We estimated influenza VE against influenza-associated hospitalization among children aged 6-72 months in the district of Foggia, Southern Italy.

methodsWe conducted a test-negative case-control study among children hospitalized for acute respiratory infection and tested for influenza during the 2022-2023 to 2025-2026 influenza seasons. Cases were influenza-positive children and controls were influenza-negative children. VE was estimated as (1 - odds ratio) x 100; adjusted VE was derived from multivariable logistic regression models.

resultsThe study included 935 children, of whom 207 were influenza-positive cases and 728 were influenza-negative controls. Adjusted VE was 62.5% (95% CI: 34.4%-78.5%) for receipt of at least one influenza vaccine dose and 61.9% (95% CI: 29.3%-79.4%) for full vaccination. By vaccine type, adjusted VE was 80.3% (95% CI: 43.8%-93.1%) for at least one dose of LAIV and 50.9% (95% CI: 6.9%-74.2%) for at least one dose of IIV. Season-specific adjusted VE was highest in 2024-2025, reaching 92.2% (95% CI: 65.6%-98.2%) for at least one dose and 90.7% (95% CI: 58.5%-97.9%) for full vaccination.

conclusionsInfluenza vaccination was associated with a reduced risk of influenza-associated hospitalization among children aged 6-72 months, with the strongest protection observed during the 2024-2025 season. These findings support continued efforts to improve pediatric influenza vaccination uptake.

Indexed as

HospitalizationInfluenzaPediatricsTest-negative designVaccinationVaccine effectiveness

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.